Literature DB >> 8621540

Direct binding of C-terminal region of p130Cas to SH2 and SH3 domains of Src kinase.

T Nakamoto1, R Sakai, K Ozawa, Y Yazaki, H Hirai.   

Abstract

p130Cas is a major tyrosine-phosphorylated protein that tightly binds v-Crk in v-crk-transformed cells and v-Src in v-src-transformed cells. The "substrate domain" of p130Cas contains 15 possible Src homology (SH) 2-binding motifs, most of which conform to the binding motif for the Crk SH2 domain. Another region near its C terminus contains possible binding motifs for the Src SH2 domain and proline-rich sequences that are candidates for SH3-binding sites. Using GST fusion proteins, we revealed that both SH2 and SH3 domains of Src bind p130Cas, whereas v-Crk binds p130Cas through its SH2 domain. We located the binding site of p130Cas for the Src SH3 domain at the sequence RPLPSPP in the region near its C terminus. Mutations within this sequence or at Tyr762 of p130Cas caused a significant reduction in the association of p130Cas with Src, and no association was detected when both of them were deleted. The kinase activity in v-Crk-transformed cells was also associated with p130Cas through this region. On the other hand, the deletion of the substrate domain abolished the binding with v-Crk. The association through the C-terminal region of p130Cas with Src kinase may facilitate effective hyperphosphorylation of tyrosine residues in the substrate domain of p130Cas, resulting in the binding of SH2-containing molecules to p130Cas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8621540     DOI: 10.1074/jbc.271.15.8959

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  Proteolysis of the docking protein HEF1 and implications for focal adhesion dynamics.

Authors:  G M O'Neill; E A Golemis
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 2.  Determinants of substrate recognition in nonreceptor tyrosine kinases.

Authors:  W Todd Miller
Journal:  Acc Chem Res       Date:  2003-06       Impact factor: 22.384

3.  Deregulation of HEF1 impairs M-phase progression by disrupting the RhoA activation cycle.

Authors:  Disha Dadke; Michael Jarnik; Elena N Pugacheva; Mahendra K Singh; Erica A Golemis
Journal:  Mol Biol Cell       Date:  2006-01-04       Impact factor: 4.138

4.  Crystallization of the SH2-binding site of p130Cas in complex with Lck, a Src-family kinase.

Authors:  Fariborz Nasertorabi; Andres Alonso; Scott W Rogers; Tomas Mustelin; Kristiina Vuori; Lars Liljas; Kathryn R Ely
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2005-01-08

5.  Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells.

Authors:  Gary S Goldberg; David B Alexander; Patricia Pellicena; Zhong-Yin Zhang; Hiroyuki Tsuda; W Todd Miller
Journal:  J Biol Chem       Date:  2003-09-11       Impact factor: 5.157

6.  Focal adhesions require catalytic activity of Src family kinases to mediate integrin-matrix adhesion.

Authors:  Leiming Li; Masaya Okura; Akira Imamoto
Journal:  Mol Cell Biol       Date:  2002-02       Impact factor: 4.272

7.  Cooperative activation of Src family kinases by SH3 and SH2 ligands.

Authors:  Shalini S Yadav; W Todd Miller
Journal:  Cancer Lett       Date:  2007-08-24       Impact factor: 8.679

8.  Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src.

Authors:  P J Ruest; N Y Shin; T R Polte; X Zhang; S K Hanks
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

9.  SRC points the way to biomarkers and chemotherapeutic targets.

Authors:  Harini Krishnan; W Todd Miller; Gary S Goldberg
Journal:  Genes Cancer       Date:  2012-05

10.  P130Cas-associated protein (p140Cap) as a new tyrosine-phosphorylated protein involved in cell spreading.

Authors:  Paola Di Stefano; Sara Cabodi; Elisabetta Boeri Erba; Valentina Margaria; Elena Bergatto; Maria Gabriella Giuffrida; Lorenzo Silengo; Guido Tarone; Emilia Turco; Paola Defilippi
Journal:  Mol Biol Cell       Date:  2003-12-02       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.